Korean-style ARPA-H backing for ASO pipeline

The project is part of Korea's homegrown version of ARPA-H, the U.S. health research agency known for high-risk, high-reward biomedical programs. Under the roughly 8 billion won (about $6 million) program, Threebillion will work on an ASO therapy targeting rare diseases.

ASOs are short synthetic strands of genetic material designed to correct or modulate gene expression, an approach that has gained traction in rare disease treatment where small-molecule drugs often fall short. Threebillion specializes in this modality, using its platform to design candidate molecules aimed at genetic conditions with limited treatment options.

Funding figures and program details were reported based on the company's selection announcement; further specifics on the target indication and development timeline remain unconfirmed.

Verdict: Mostly True